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LETTERS TO THE EDITORKNOWING THE COST OF
CARDIAC SURGICAL
COMPLICATIONS: DOES IT
REALLY REDUCE THEM OR
IMPROVE QUALITY?
To the Editor:
I read with interest the article by
Christensen and colleagues1 about
the incremental costs of postoperative
hemorrhage in cardiac surgery, a com-
mon complication. I agree with the
authors that measures to prevent or de-
crease postoperative hemorrhage are
important in cost-effectiveness. In
fact, all cardiac surgical complications
are associated with substantial added
cost, as shown in several articles.2
Cardiac surgery has its own special
peculiarities that make it different
from any other kind of surgery. It has
the widest spectrum of complications,
most of them are fatal. With regard to
the etiology of postoperative hemor-
rhage, a great deal is attributable to
the vast array of antiplatelet and
thrombolytic agents given before sur-
gery by referring cardiologists. Most
other causes mentioned by Christen-
sen and colleagues1 are usually un-
avoidable.
It is difficult to calculate the exact
cost of each individual complication,
because complications usually start
as one kind and rapidly move on to
another in a cascade pattern, ending
this vicious circle with multiorgan
failure and death. Postoperative renal
failure necessitating hemodialysis,
prolonged need for ventilation, and
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The Journalpensive complications, by far exceed-
ing the cost of bleeding. All these
complications deserve preventive
measures, but because of their harm-
ful effects on the patients rather than
for cost containment.
Avoiding complications is much
better than handling and overcoming
them. Careful selection of patients
who will benefit most with the least
trouble is the criterion standard of the
ideal patient. Quality improvement in
this multidisciplinary and delicate ser-
vice requires a comprehensive under-
standing of the basics and details of
the surgical procedures, not the incre-
mental costs of complications.
Morbidity and mortality can not be
‘‘priced’’ financially, because there is
no winner in this deal. Both the patient
and the health service are losers.
Knowing the added cost will never re-
duce the complications. Death, the
most disastrous complication, is actu-
ally the cheapest, with no extra cost
to be paid. In a series from my own
group,3 lifelong hemodialysis was the
most expensive complication, fol-
lowed by a patient being ‘‘stuck’’ on
the ventilator.
The most important feature of car-
diac surgery is that only a certain sub-
set of cardiac patients, according to
clinical guidelines, will benefit from
surgery. All cardiac procedures, ex-
cept patent ductus arteriosus ligation,
are palliative. The ongoing atheroscle-
rosis progression will sooner or later
‘‘block’’ the grafts. Valve replace-
ment, as the name implies, actually
replaces one disease condition with
another. The concept of ‘‘do no
harm’’ must be exercised with every
cardiac patient. Health care providers
must avoid complications because of
this concept, not because of extra
cost. Candidates at very high risk
who will receive only marginal surgi-
cal benefit should not undergo surgery.
Cardiac patients must be considered
according to the indication and type
of surgical procedure and assessed ac-
cording to the international risk stratifi-
cation scores. Strict adherence toof Thoracic and Cardiovascular Surgerevidence-basedmedicine must be rein-
forced and practiced by the referring
cardiologist, cardiac anesthetist, perfu-
sionist, surgical team, and intensive
care staff. A successful cardiac proce-
dure is the outcome of perfect perfor-
mance by all these team members in
conjunction with the previously men-
tioned patient factors.
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We naturally agree with Dr Al-
Ebrahim that avoiding complications
in cardiac surgery is far better than treat-
ing themas theyoccur; however,webe-
lieve that some key messages of our
research have been misunderstood. Dr
Al-Ebrahim states, ‘‘Quality improve-
ment in this multidisciplinary and deli-
cate service requires comprehensive
understanding of the basics and details
of the surgical procedures, and the in-
cremental costs of complications. Mor-
bidity and mortality can not be
‘‘priced’’ financially, because there is
no winner in this deal. Both the patient
and the health service are losers. Know-
ing the added cost will never reduce the
complications. Death, the most disas-
trous complication, is actually the
cheapest, with no extra cost to be
paid.’’ Although it is correct that mor-
bidity and mortality cannot be priced,
the costs of treating medicaly c Volume 139, Number 6 1667
